The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- WHO: Spike in Violence in DRC Threatens Progress Made in Ebola Fighton November 22, 2019 at 11:49 am
EU Approval of First Ebola Vaccine is Game Changer WHO calls the approval of the Ebola vaccine a landmark moment for global health and a likely game-changer in the battle against this deadly disease ...
- Ebola Virus Vaccine Approved Worldwide, Saves Hundreds Of Thousands Of Liveson November 18, 2019 at 3:40 am
The World Health Organization (WHO), within 48 hours of the approval of the European Commission of the vaccine this week, stated that it is now available for global use. This came to light as the ...
- Ebola Vaccine Market In-depth Analysis and Detailed Survey by 2026on November 17, 2019 at 9:07 pm
Nov 18, 2019 (Heraldkeepers) -- According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and ...
- Finally, An Ebola Vaccineon November 14, 2019 at 9:13 pm
The EU has approved an Ebola vaccine. Credit: UC Rusal Photo Gallery/CC BY 2.0 Christopher Intagliata is Science Friday’s senior producer. He once served as a prop in an optical illusion and speaks ...
- At Ebola ground zero in DR Congo, new vaccine offers hopeon November 14, 2019 at 10:17 am
Ebola is no longer incurable. Treatments have been successful 90 percent of the time when symptoms were detected early. People who were given the vaccine manufactured by Merck, a German pharmaceutical ...
- There is finally an approved Ebola vaccineon November 14, 2019 at 9:22 am
There’s big news this week in the fight against infectious disease: the world now has an approved Ebola vaccine. It is the first vaccine of its kind to be approved for quality, safety, and ...
- First Ebola vaccine prequalified by WHO for use in high-risk countrieson November 14, 2019 at 5:51 am
The world's first Ebola vaccine has been prequalified by the World Health Organization (WHO), a key step in speeding up its licensing, access, and use in countries most at risk of Ebola outbreaks.
- Rollout of Johnson & Johnson Ebola vaccine begins in Congoon November 14, 2019 at 3:56 am
GOMA, Congo (Reuters) - Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson & Johnson, aid group MSF said on Thursday, to help combat the world’s second-worst ...
- Second Ebola vaccine introduced in DR Congoon November 14, 2019 at 3:40 am
Goma (DR Congo) (AFP) - The Democratic Republic of Congo on Thursday introduced a second vaccine to fight a 15-month-old epidemic of Ebola in the east of the country, Doctors Without Borders (MSF) ...
- Ervebo approved as 1st Ebola vaccineon November 13, 2019 at 1:04 pm
The world's first Ebola vaccine is finally approved, a critical move that opens the door for its use in countries at high risk for the infectious disease. Just 48 hours after the European Commission ...
via Google News and Bing News